There are currently 1547 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971
Recruiting
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/28/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/28/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland +1 locations
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
Mindfulness Based Stress Reduction App
NCT06079840
Recruiting
African American caregivers of people living with HIV/AIDS (PLWHA) have unique needs because they are more likely to experience stressors related to intersecting sources of stigma, discrimination, and caregiving burdens specifically associated with caregiving for PLWHA. The proposed project will enhance and finalize Phase I app development and evaluate its effectiveness in a randomized controlled trial. The project has high public health significance because of its potential to provide an access... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/28/2025
Locations: Friends Research Institute, Baltimore, Maryland
Conditions: Stress Reduction
Register for Updates
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847
Recruiting
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/28/2025
Locations: John Hopkins Hospital, Baltimore, Maryland
Conditions: Neurofibromatosis Type 1
Register for Updates
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
NCT05154513
Recruiting
IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.
Gender:
ALL
Ages:
All
Trial Updated:
04/28/2025
Locations: Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland
Conditions: HIV Infection
Register for Updates
Proton SBRT for Spinal Metastasis
NCT06895564
Recruiting
This is a single-arm pilot study of proton stereotactic body radiotherapy (SBRT) for nonhematologic spinal metastasis in patients with complex lesions that are unable to be effectively treated with standard of care photon SBRT defined as inability to develop a photon SBRT plan that achieves adequate coverage (≥80% planning treatment volume (PTV) coverage)) with a prescription dose of 30 Gy in 5 fractions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Spinal Metastasis
Register for Updates
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122
Recruiting
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/28/2025
Locations: The Johns Hopkins University, Baltimore, Maryland
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737
Recruiting
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/28/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Cutaneous Lupus Erythematosus
Register for Updates
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Maryland Cardiovascular Specialists - Baltimore, Baltimore, Maryland
Conditions: Heart Failure, Systemic Inflammation
Register for Updates
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT05636176
Recruiting
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Ascension Saint Agnes Heart Ca, Baltimore, Maryland +1 locations
Conditions: Heart Failure
Register for Updates
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709
Recruiting
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/27/2025
Locations: Univ of MD Schl of Med, Baltimore, Maryland
Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Register for Updates